Ducentis Biotherapeutics Secures £5.9m to Advance Inflammatory Disease Therapies

Ducentis Biotherapeutics Ltd., a Bristol-based preclinical-stage biotechnology company, has successfully raised £5.9m in its latest funding round. The funding, with an allotment date of 20 April 2026 and filed on 29 April 2026, will support the continued development of its novel therapies for inflammatory and autoimmune diseases.

Founded on 12 November 2014, Ducentis Biotherapeutics is focused on addressing significant unmet medical needs within the inflammatory and autoimmune disease landscape. The company's primary therapeutic candidate, DS-234, is a fusion protein specifically designed to target the CD200/CD200R axis. This innovative approach is currently being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition affecting millions worldwide.

Financially, the company reported a profit/loss of £-7,839,323 in its latest available accounts, reflecting the substantial investment typically required for preclinical biotechnology research and development.

This latest £5.9m capital injection marks another significant step in Ducentis Biotherapeutics' funding journey. The company has demonstrated a consistent ability to attract investment, with a series of rounds over recent years. Prior to this, Ducentis secured £7.9m on 27 June 2025, and £3.1m on 23 December 2024. Earlier rounds include £1.7m on 12 October 2022, £1.4m on 9 September 2022, and £68.1k on 28 June 2022. The company's earlier funding history also includes a £1.5m round on 19 June 2019, a £200k round on 17 October 2019, a £60k round on 2 December 2019, a £32k round on 6 August 2019, and a £246.1k round on 4 April 2019, which was at a reported valuation of £3m. The consistent flow of capital underscores investor confidence in the company's scientific platform and its potential to bring new treatments to market.

The funding round for Ducentis Biotherapeutics comes as the UK biotech sector shows signs of recovery and adaptation within a dynamic investment landscape. While 2025 was characterised by a challenging financing environment, with UK biotech securing £1.9 billion in equity financing, a 13.2% decrease year-on-year in venture capital investment, the sector ended the year with renewed momentum. Despite the downturn in overall venture capital, the UK maintained its position as Europe's leading national biotech market, accounting for 30% of all European venture financing in 2025.

Entering 2026, the first quarter saw positive shifts, with total equity financing for UK biotech companies reaching £552 million, an 18% increase from the £466 million raised in Q4 2025. Venture capital investment specifically rose by 17% to £516 million in Q1 2026, compared to £442 million in the previous quarter. This period also witnessed a surge in deal activity, with 25 transactions completed in Q1 2026, a significant increase from 15 deals in Q1 2025, indicating a broader distribution of capital across companies and a move away from a reliance on a few mega-rounds. Late-stage funding rounds, specifically Series B and beyond, attracted the largest share of capital in Q1 2026, totalling £276 million.

However, the public markets continued to face challenges, with no UK biotech IPOs in Q1 2026, extending a nearly four-year period without new listings. In contrast, mergers and acquisitions (M&A) activity remained a strong point, providing a vital route to liquidity and validating the strategic value of UK biotech assets. Ducentis Biotherapeutics' successful £5.9m raise aligns with the observed trend of sustained venture capital interest in innovative UK life sciences companies, particularly those in preclinical development, as investors continue to back promising scientific platforms despite broader market selectivity.